FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Edith Huland

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Neoplasm Staging

Co-author Network

Publications

TOP 3
D Loppow; Edith Huland; Hans Heinzer; Lars Grönke; Helgo Magnussen; Olaf Holz; Rudolf A Jörres
Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation.
Maryam Aalamian-Matheis; Gurkamal S Chatta; Michael R Shurin; Edith Huland; Hartwig Huland; Galina V Shurin
Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA.
Jens Atzpodien; Holger Kirchner; U Rebmann; M Soder; U Gertenbach; Michael Siebels; Jan Roigas; R Raschke; S Salm; B Schwindl; S C Müller; S Hauser; C Leiber; Edith Huland; Hans Heinzer; S Siemer; Bernd Metzner; Hans Heynemann; P Fornara; Martina Reitz
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Edith Huland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: D Loppow; Edith Huland; Hans Heinzer; Lars Grönke; Helgo Magnussen; Olaf Holz; Rudolf A Jörres
Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation.
European journal of medical research 2007;12(11):556-62.
2007: Maryam Aalamian-Matheis; Gurkamal S Chatta; Michael R Shurin; Edith Huland; Hartwig Huland; Galina V Shurin
Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA.
Advances in experimental medicine and biology 2007;601():173-82.
2006: Jens Atzpodien; Holger Kirchner; U Rebmann; M Soder; U Gertenbach; Michael Siebels; Jan Roigas; R Raschke; S Salm; B Schwindl; S C Müller; S Hauser; C Leiber; Edith Huland; Hans Heinzer; S Siemer; Bernd Metzner; Hans Heynemann; P Fornara; Martina Reitz
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
British journal of cancer 2006;95(4):463-9.
2004: Edith Huland; Hans Heinzer; R A Jörres; D Loppow; Hartwig Huland
Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy.
Der Urologe. Ausg. A 2004;43 Suppl 3():S140-4.
2004: Edith Huland; Hans Heinzer
Renal cell carcinoma - innovative medical treatments.
Current opinion in urology 2004;14(4):239-44.
2003: Alexander Haese; Markus Graefen; Thomas Steuber; Charlotte Becker; Joachim Noldus; Andreas Erbersdobler; Edith Huland; Hartwig Huland; Hans Lilja
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
The Journal of urology 2003;170(6 Pt 1):2269-73.
2003: Hans Heinzer; Edith Huland; Hartwig Huland
[Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the elderly patient].
Der Urologe. Ausg. A 2003;42(11):1450-2.
2003: Edith Huland; Hans Heinzer
Renal cell carcinoma: novel treatments for advanced disease.
Current opinion in urology 2003;13(6):451-6.
2003: Maryam Aalamian; Irina L Tourkova; Gurkamal S Chatta; Hans Lilja; Edith Huland; Hartwig Huland; Galina V Shurin; Michael R Shurin
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
The Journal of urology 2003;170(5):2026-30.
2003: Alexander Haese; Markus Graefen; Jüri Palisaar; Edith Huland; Hartwig Huland
[Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Der Urologe. Ausg. A 2003;42(9):1172-87.
2003: Alexander Haese; Markus Graefen; Charlotte Becker; Joachim Noldus; Jared Katz; Ilias Cagiannos; Michael W Kattan; Peter T Scardino; Edith Huland; Hartwig Huland; Hans Lilja
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
The Prostate 2003;54(3):181-6.
2003: Edith Huland; A Burger; J Fleischer; Paolo Fornara; E Hatzmann; A Heidenreich; Hans Heinzer; Hans Heynemann; L Hoffmann; R Hofmann; Hartwig Huland; I Kämpfer; M Kindler; H Kirchner; G Mehlhorn; T H Moniak; U Rebmann; Jan Roigas; T H Schneider; D Schnorr; H J Schmitz; R Wenisch; Z Varga; J Vinke
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study.
Folia biologica 2003;49(5):183-90.
2002: Martin G Friedrich; Angelika Hellstern; Stefan H Hautmann; Markus Graefen; Stefan Conrad; Edith Huland; Hartwig Huland
Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
The Journal of urology 2002;168(2):470-4.
2002: Edith Huland; Hans Heinzer; S Timm; M Alamian; Hartwig Huland
[Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status].
Der Urologe. Ausg. A 2002;41(3):282-7.
2002: Hans Heinzer; Edith Huland; Hartwig Huland
[Regional immunotherapy of metastatic renal cell carcinoma].
Der Urologe. Ausg. A 2002;41(3):239-48.
2002: J E Gschwend; Edith Huland
[Metastatic renal cell carcinoma].
Der Urologe. Ausg. A 2002;41(3):219-20.
2002: Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; Peter Hammerer; Alexander Haese; Jüri Palisaar; Edith Huland; Peter T Scardino; Michael W Kattan; Hartwig Huland
Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
The Journal of urology 2002;167(3):1306-9.
2002: Hartwig Huland; Markus Graefen; Alexander Haese; Peter Hammerer; Jüri Palisaar; Uwe Pichlmeier; Rolf-Peter Henke; Andreas Erbersdobler; Edith Huland; Hans Lilja
Prediction of tumor heterogeneity in localized prostate cancer.
The Urologic clinics of North America 2002;29(1):213-22.
2002: R Jüri Palisaar; Markus Graefen; Pierre I Karakiewicz; Peter Hammerer; Edith Huland; Alexander Haese; Salvador Fernandez; Andreas Erbersdobler; Rolf-Peter Henke; Hartwig Huland
Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.
European urology 2002;41(2):155-61.
2001: Hans Heinzer; Edith Huland; Hartwig Huland
Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer.
World journal of urology 2001;19(2):111-9.
2001: Galina V Shurin; Maryam Aalamian; Georgi Pirtskhalaishvili; Svetlana N Bykovskaia; Edith Huland; Hartwig Huland; Michael R Shurin
Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors.
European urology 2001;39 Suppl 4():37-40.
2001: Martin G Friedrich; Sabine Riethdorf; Andreas Erbersdobler; C Tiemer; Hartwig Schwaibold; J K Sölter; Edith Huland; Lutz Riethdorf; Stefan Conrad; Peter Hammerer; Hartwig Huland
Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.
European urology 2001;39(2):159-66.
2001: Edith Huland
Interleukin-2 and cancer--physiological and pharmacological uses.
Folia biologica 2001;47(4):111-2.
2001: Maryam Aalamian; Georgi Pirtskhalaishvili; A Nunez; Clemens Esche; Galina V Shurin; Edith Huland; Hartwig Huland; Michael R Shurin
Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells.
The Prostate 2001;46(1):68-75.
2000: Peter Hammerer; Markus Graefen; Rolf-Peter Henke; Alexander Haese; Jüri Palisaar; Edith Huland; Hartwig Huland
Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy.
Anticancer research 2000;20(6D):5253-5.
2000: Stefan H Hautmann; Edith Huland; A Wullbrand; M Friedrich; Hartwig Huland
Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps.
Anticancer research 2000;20(6B):4495-8.
2000: H Hilz; M Graefen; Joachim Noldus; P Hammerer; C Knabbe; Edith Huland; H Huland
Advanced prostate cancer is associated with a decrease in serum luteinizing hormone.
European urology 2000;38(3):243-9.
2000: Hans Heinzer; Edith Huland; Hartwig Huland
[Treatment of metastatic renal cell carcinoma. Value of immunotherapy compared with surgery of metastases].
Der Urologe. Ausg. A 2000;39(4):356-61.
2000: Stefan H Hautmann; Edith Huland; C Grupp; A Haese; H Huland
Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer.
Anticancer research 2000;20(3B):2151-4.
2000: J Bubeník; W Den Otter; Edith Huland
Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines.
Cancer immunology, immunotherapy : CII 2000;49(2):116-22.
2000: Alexander Haese; Charlotte Becker; Joachim Noldus; Markus Graefen; Edith Huland; Hartwig Huland; Hans Lilja
Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
The Journal of urology 2000;163(5):1491-7.
2000: Martin G Friedrich; Andreas Erbersdobler; Hartwig Schwaibold; Stefan Conrad; Edith Huland; Hartwig Huland
Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
The Journal of urology 2000;163(3):1039-42.
2000: Edith Huland; Hans Heinzer; Hartwig Huland; R Yung
Overview of interleukin-2 inhalation therapy.
The cancer journal from Scientific American 2000;6 Suppl 1():S104-12.
2000: Edith Huland; Hans Heinzer; Hartwig Huland
A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
Folia biologica 2000;46(6):241-50.
2000: Edith Huland; Hans Heinzer
Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.
British journal of cancer 2000;82(1):246-7.
1999: Hans Lilja; Alexander Haese; Thomas Björk; M G Friedrich; Timo Piironen; Kim Pettersson; Edith Huland; Hartwig Huland
Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
The Journal of urology 1999;162(6):2029-34; discussion 2034-5.
1999: Hans Heinzer; TS Mir; Edith Huland; Hartwig Huland
Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3612-20.
1999: Hans Heinzer; Edith Huland; Maryam Aalamian; Hartwig Huland
[Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter].
Der Urologe. Ausg. A 1999;38(5):466-73.
1999: Edith Huland; Hans Heinzer; Hartwig Huland
Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).
Anticancer research 1999;19(4A):2679-83.
1999: Stefan H Hautmann; Edith Huland; Hartwig Huland
Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth.
Anticancer research 1999;19(4A):2661-3.
1999: Alexander Haese; Edith Huland; Markus Graefen; Hartwig Huland
Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
Anticancer research 1999;19(4A):2641-4.
1999: Edith Huland; Hans Heinzer; H Huland
Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
Hepato-gastroenterology 1999;46 Suppl 1():1257-62.
1999: Alexander Haese; Edith Huland; Markus Graefen; P Hammerer; Joachim Noldus; Hartwig Huland
Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
The Journal of urology 1999;161(4):1206-11.
1999: Markus Graefen; Joachim Noldus; Uwe Pichlmeier; A Haese; P Hammerer; Salvador Fernandez; S Conrad; Rolf-Peter Henke; Edith Huland; Hartwig Huland
Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
European urology 1999;36(1):21-30.
1998: Joachim Noldus; Markus Graefen; Edith Huland; C Busch; P Hammerer; Hartwig Huland
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.
The Journal of urology 1998;159(6):2004-7; discussion 2007-8.
1998: Markus Graefen; Peter Hammerer; Uwe Michl; Joachim Noldus; Alexander Haese; Rolf-Peter Henke; Edith Huland; Hartwig Huland
Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy.
Urology 1998;51(3):437-42.
1997: Edith Huland; Hans Heinzer; TS Mir; Hartwig Huland
Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience.
The cancer journal from Scientific American 1997;3 Suppl 1():S98-105.
1997: Alexander Haese; Markus Graefen; Joachim Noldus; P Hammerer; Edith Huland; Hartwig Huland
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
The Journal of urology 1997;158(6):2188-92.
1997: Raj S Pruthi; A Haese; Edith Huland; Thomas A Stamey
Use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy.
Urology 1997;49(3):404-10.
1997: E Lee; Hartwig Schwaibold; Y Fradet; Edith Huland; Hartwig Huland
Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder.
The Journal of urology 1997;157(3):1070-3.
1997: Stefan H Hautmann; Edith Huland; Hartwig Huland
Intratumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats.
Journal of cancer research and clinical oncology 1997;123(11-12):614-8.
1996: J Lorenz; K Wilhelm; M Kessler; C Peschel; U Schwulera; R Lissner; Wilhelm G. Struff; Edith Huland; Christoph Huber; Walter Aulitzky
Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(7):1115-22.
1996: Hartwig Huland; Peter Hammerer; Rolf-Peter Henke; Edith Huland
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies.
The Journal of urology 1996;155(4):1344-7.
1995: Edith Huland; Hartwig Schwaibold; R Klän; Hartwig Huland
Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer.
Urology 1995;45(1):54-7; discussion 57-8.
1995: Edith Huland; B Falk; D Hübner; Hartwig Huland
In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors.
Journal of cancer research and clinical oncology 1995;121(5):285-90.
1995: Hartwig Schwaibold; Edith Huland; Hans Heinzer; U Schwuléra; Hartwig Huland
Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder.
Journal of cancer research and clinical oncology 1995;121(4):239-46.
1994: Edith Huland; Hans Heinzer; Hartwig Huland
Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
Journal of cancer research and clinical oncology 1994;120(4):221-8.
1993: Edith Huland; A Schneider; H Huland
Immunocytology as a possible marker to identify patients who require prophylaxis.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;126():143-50.
1993: Hans Heinzer; K P Dieckmann; Edith Huland
Virus-related serology and in situ hybridization for the detection of virus DNA among patients with testicular cancer.
European urology 1993;24(2):271-6.
1992: Hans Heinzer; Edith Huland; M Mönk; Hartwig Huland
Distribution of 486P 3/12 antigen, ABO(H) blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder.
The Journal of urology 1992;148(3):802-5.
1992: Hans Heinzer; Edith Huland; Hartwig Huland
Adverse reaction to contrast material in a patient treated with local interleukin-2.
AJR. American journal of roentgenology 1992;158(6):1407.
1992: Edith Huland; Hartwig Huland; Hans Heinzer
Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma.
The Journal of urology 1992;147(2):344-8.
1992: Edith Huland; H Huland
Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells.
Journal of cancer research and clinical oncology 1992;118(6):463-7.
1991: Edith Huland; Hartwig Huland; T Meier; O Baricordi; Y Fradet; H B Grossman; G M Hodges; E M Messing; B J Schmitz-Draeger
Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder.
The Journal of urology 1991;146(6):1631-6.
1991: R Klän; Edith Huland; H Baisch; Hartwig Huland
Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486 P3/12 in 241 unselected patients with bladder carcinoma.
The Journal of urology 1991;145(3):495-7.
1990: Edith Huland; Hartwig Huland; A W Schneider
Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxis.
The Journal of urology 1990;144(3):637-9; discussion 639-40.
1990: Hartwig Huland; G Klöppel; I Feddersen; U Otto; W Brachmann; H Hubmann; J Kaufmann; W Knipper; F Lantzius-Beninga; Edith Huland
Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.
The Journal of urology 1990;144(1):68-71; discussion 71-2.
1990: H Huland; A Schneider; Edith Huland; R Arndt
Immunocytology as a possible marker to identify patients who require prophylaxis.
Progress in clinical and biological research 1990;350():35-9.
1989: Edith Huland; H Huland
Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.
Cancer research 1989;49(19):5469-74.
1989: A W Schneider; Edith Huland; Hartwig Huland
[Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers].
Der Urologe. Ausg. A 1989;28(5):289-91.
1988: Hartwig Huland; U Otto; R Arndt; Edith Huland
Experimental studies on the heterogeneity of bladder carcinoma.
European urology 1988;14 Suppl 1():11-4.
1988: R Arndt; Peter Hammerer; Edith Huland; H Krämer-Hansen; Hartwig Huland
Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulin.
Urologia internationalis 1988;43(3):139-44.
1987: H Huland; R Arndt; Edith Huland; T Loening; M Steffens
Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytology.
The Journal of urology 1987;137(4):654-9.
1986: Edith Huland; R Arndt; H Huland
Human transitional cell carcinoma in the NMRI-nu/nu mouse bladder: a new animal model for the in vivo use of monoclonal antibodies and cytotoxic agents.
Cancer research 1986;46(5):2488-9.
1985: M E Blank; F Bode; Edith Huland; D F Diedrich; K Baumann
Kinetic studies of D-glucose transport in renal brush-border membrane vesicles of streptozotocin-induced diabetic rats.
Biochimica et biophysica acta 1985;844(3):314-9.